Glaucoma in the United States and Europe: Predicting costs and surgical rates based upon stage of disease

Journal of Glaucoma

Volumn 16, Issue 5, 2007, Pages 471-478

  Lee, Paul P ^a   Kelly, Simon P ^b   Mills, Richard P ^c   Traverso, Carlo E ^d   Walt, John G ^e   Doyle, John J ^f   Katz, Laura M ^f   Siegartel, Lisa R ^f  

^a DUKE UNIVERSITY   (United States)

^b BOLTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF GENOA   (Italy)

^e ALLERGAN INC   (United States)

^f Analytica International   (United States)

Author keywords

Europe; Glaucoma; Health economics; Progression; United States

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EUROPE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; TRABECULECTOMY; UNITED STATES; VISUAL FIELD;

AGED; ANTIHYPERTENSIVE AGENTS; COST OF ILLNESS; DISEASE PROGRESSION; ECONOMICS, MEDICAL; EUROPE; FEMALE; FILTERING SURGERY; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES RESEARCH; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 34547865335     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3180575202     Document Type: Article

References (52)

1. Caprioli J, Bateman JB, Gaasterland DE. Preferred Practice Pattern™: Primary Open-angle Glaucoma. San Francisco: American Academy of Ophthalmology; 2000:5-10.
2. Nuzzi R, Cerruti A. Epidemiological aspects, development and management of prevention in ophthalmology in relation to different ages. Panminerva Med. 1995;37:28-37.
3. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
4. Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma. 2001;10:184-191.
5. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma. 2002;11:531-539.
6. Lee PP, Feldman ZW, Ostermann J, et al. Longitudinal prevalence of major eye diseases. Arch Ophthalmol. 2003;121:1303-1310.
7. Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma. 2003;12:456-462.
8. Kobelt G, Jonsson L. Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care. 1999;15:207-219.
9. Rouland JF, Le Pen C. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol. 2003;13(suppl 4):S5-S20.
10. Glick H, Brainsky A, McDonald RC, et al. The cost of glaucoma in the United States in 1988. Chibret Int J Ophthalmol. 1994;10:6-12.
11. Kobelt G, Jonsson L, Gerdtham U, et al. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol. 1998;236:811-821.
12. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma. 1998;7:95-104.
13. Fiscella RG, Green A, Patuszynski DH, et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol. 2003;136:18-25.
14. Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma. 2002;11:354-358.
15. Bernard LM, Althin R, Dhawan R, et al. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol. 2003;13(suppl 4):S30-S43.
16. Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother. 2003;4:1775-1788.
17. Jonsson B, Krieglstein G. Primary open-angle glaucoma - differences in international treatment patterns and costs. 1999:45-106.
18. Mills RP, Budenz DL, Lee PP, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006;141:24-30.
19. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124:12-19.
20. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89:1245-1249.
21. France Costs: "Base Nationale PMSI - Année 2000": ATIH, Ministère de l'Emploi et de la Solidarité; 2000.
22. Germany Costs: EBM (Statutory doctors fee scale) and GOA (Private doctors fee scale); 2002.
23. Italy Costs: CEIS - Health Economics and Health Care Management; 2002.
24. United Kingdom Costs: Department of Health, NHS Costing Manual: Department of Health, London; 2003.
25. Physicians Fee & Coding Guide. Georgia: HealthCare Consultants of America, Inc. MAG Mutual Group; 2001.
26. Overview of HCUP Nationwide Inpatient Sample (NIS) 2000. Rockville: Agency for Healthcare Research and Quality (AHRQ); 2002.
27. Calissendorff BM. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand. 2001;79:286-288.
28. Cardinale V, ed. Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 2001.
29. Davis JB, pub. Medical Fees in the United States. Nationwide Charges for Medicine, Surgery, Laboratory, Radiology, and Allied Health Services. Los Angeles: Practice Management Information Corporation; 2001.
30. Coleman AL, Brigatti L. The glaucomas. Minerva Med. 2001;92:365-379.
31. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
32. Gray SF, Spry PG, Brookes ST, et al. The Bristol shared care glaucoma study: outcome at follow up at 2 years. Br J Ophthalmol. 2000;84:456-463.
33. Kroese M, Burton H, Vardy S, et al. Prevalence of primary open angle glaucoma in general ophthalmic practice in the United Kingdom. Br J Ophthalmol. 2002;86:978-980.
34. Cerulli L, Cedrone C, Cesareo M, et al. L'epidemiologia del glaucoma. In: Cerulli L, Miglior M, Ponte F, eds. L'epdimeiologia in Italia. Rome: Relazione ufficiale al LXXVII Congresso della Società Oftalmologica Italiana, Inc; 1997:163-246.
35. Bonomi L, Marchini G, Marraffa M, et al. The relationship between intraocular pressure and glaucoma in a defined population. Data from the Egna-Neumarkt Glaucoma Study. Ophthalmologica. 2001;215:34-38.
36. Krumpaszky HG, Ludtke R, Mickler A, et al. Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern. Ophthalmologica. 1999;213:176-182.
37. Trautner C, Haastert B, Richter B, et al. Incidence of blindness in southern Germany due to glaucoma and degenerative conditions. Invest Ophthalmol Vis Sci. 2003;44:1031-1034.
38. Alward WL. Medical management of glaucoma. N Engl J Med. 1998;339:1298-1307.
39. Cantor L. Achieving low target pressures with today's glaucoma medications. Surv Ophthalmol. 2003;48(suppl 1):S8-S16.
40. Fingeret M. Glaucoma medications, glaucoma therapy, and the evolving paradigm. J Am Optom Assoc. 1998;69:115-121.
41. Paikal D, Yu F, Coleman AL. Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998. Ophthalmology. 2002;109:1372-1376.
42. Baudouin C, Rouland JF, Le Pen C. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France. Eur J Ophthalmol. 2003;13(suppl 4):S53-S60.
43. Whittaker KW, Gillow JT, Cunliffe IA. Is the role of trabeculectomy in glaucoma management changing? Eye. 2001;15:449-452.
44. American Academy of Ophthalmology Glaucoma Panel. Primary Open-angle Glaucoma. Preferred practice Pattern. San Francisco: American Academy of Ophthalmology; 2000:1-36.
45. Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol. 2003;121:777-783.
46. Gricar JA, Wilson PR, Cave DG. Glaucoma. Manag Care Interface. 1998;11:42-44.
47. Bradley CA, Iskedjian M, Lanctot KL, et al. Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. Ann Pharmacother. 1995;29:681-689.
48. Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA. 2002;287:2809-2812.
49. Hattenhauer MJ, Ing D, Herman H, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1997;105:2099-2104.
50. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
51. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol. 2003;87:1201-1204.
52. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204-223.